WO2025210680 - PHARMACEUTICAL COMPOSITION OF RELUGOLIX TABLET
National phase entry is expected:
Publication Number
WO/2025/210680
Publication Date
09.10.2025
International Application No.
PCT/IN2025/050542
International Filing Date
03.04.2025
Title **
[English]
PHARMACEUTICAL COMPOSITION OF RELUGOLIX TABLET
[French]
COMPOSITION PHARMACEUTIQUE DE COMPRIMÉ DE RELUGOLIX
Applicants **
BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED
Inventors
SHAH, Dharmesh Mahendrabhai
BADIGER, Aravind Manappa
UPADHYE, Abhijeet Ashokrao
PATEL, Ketul Harshadbhai
YADAV, Sandeep Tarachand
PATIL, Kishor Prakashrao
KHATRI, Kamal Rameshbhai
Priority Data
202421027890
04.04.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1950 | |
| EPO | Filing, Examination, Granting | 11616 | |
| Japan | Filing, Examination, Granting | 1985 | |
| South Korea | Filing, Examination, Granting | 1715 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,006
Contact Us
Abstract[English]
The present invention relates to novel oral solid pharmaceutical formulation of relugolix or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient. In addition, the present invention also provides an improved process for preparation of relugolix oral solid pharmaceutical formulation. In addition, the present invention also provides better dissolution profile of relugolix oral solid dosage form.[French]
La présente invention concerne une nouvelle formulation pharmaceutique solide orale de relugolix ou d'un sel pharmaceutiquement acceptable de celui-ci et un ou plusieurs excipients pharmaceutiquement acceptables. De plus, la présente invention concerne également un procédé amélioré de préparation d'une formulation pharmaceutique solide orale de relugolix. De plus, la présente invention concerne également un meilleur profil de dissolution de la forme pharmaceutique solide orale de relugolix.